Solid Biosciences Inc.
SLDB
NASDAQ·Healthcare·Biotechnology·Mkt cap $961.9M
$9.77
▼ -3.55%
P/E
-5.43
Mkt Cap
$961.9M
52-Wk Range
$3.79–$11.45
52-Week Range
$3.79 - $11.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 79.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary dual gene expression technology enabling multiple transgenes in single vector
- Novel capsid platform for improved gene delivery and efficacy
- Strategic partnership with Ultragenyx Pharmaceutical for development and commercialization
- Focused pipeline targeting high-value rare genetic disorder with significant unmet medical need
Bear Case
1 risk
- High volatility (beta 2.4). Larger-than-normal price swings expected.
Growth
Stable outlook
Clinical trial progression of SGT-001 toward potential regulatory approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+33.1% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying SLDB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 6, 2026
Reported EPS of -$0.38 vs -$0.46 consensus (+17.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+17.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
7 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Aug 27, 2026
vs Industry
How SLDB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related